Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(33.3%)

N/A

3(33.3%)

Phase 3

2(22.2%)

Early Phase 1

1(11.1%)

9Total

Phase 2(3)

N/A(3)

Phase 3(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03960268Early Phase 1Completed

Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Role: collaborator

NCT03715049Not ApplicableCompleted

Fractional CO2 Laser System (Fraxel Repair Laser) Intended for Treatment of Perioral Rhytides/Wrinkles

Role: collaborator

NCT03497403Not ApplicableCompleted

Socket Preservation Procedure Studying Soft and Hard Tissue Outcomes

Role: collaborator

NCT01783496Not ApplicableCompleted

Thermage CPT for Treatment of Facial and Neck Laxity

Role: lead

NCT02145884Phase 2Completed

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Role: collaborator

NCT02525822Phase 2Unknown

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Role: lead

NCT02535871Phase 3Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Role: lead

NCT02537483Phase 2Unknown

A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Role: lead

NCT02491060Phase 3Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Role: lead

All 9 trials loaded